Clinical Trial Detail

NCT ID NCT03387111
Title Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors NantKwest, Inc.
Indications

head and neck squamous cell carcinoma

non-small cell lung carcinoma

Therapies

Capecitabine

nab-paclitaxel

Leucovorin

GI-6301

GI-6207

Avelumab

ETBX-021

ETBX-051

ETBX-061

Aldoxorubicin

Cisplatin

Cyclophosphamide

Bevacizumab

Necitumumab

GI-4000

Cetuximab

ALT-803

Fluorouracil

ETBX-011

Age Groups: senior adult

No variant requirements are available.